ZBH

Zimmer Biomet Holdings, Inc. Healthcare - Medical Devices Investor Relations →

YES
2.7% BELOW
↓ Approaching Was -0.5% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $106.09
14-Week RSI 57
Rel. Volume (14w) This week's trading vs. the 14-week average 1.2x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.19

Zimmer Biomet Holdings, Inc. (ZBH) closed at $103.21 as of 2026-11-13, trading 2.7% below its 200-week moving average of $106.09. This places ZBH in the below line zone. The stock is currently moving closer to the line, down from -0.5% last week. The 14-week RSI sits at 57, indicating neutral momentum.

Trading volume is running at 1.2x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.19 ratio) is neutral — neither side is clearly dominating.

Over the past 1272 weeks of data, ZBH has crossed below its 200-week moving average 18 times. On average, these episodes lasted 27 weeks. Historically, investors who bought ZBH at the start of these episodes saw an average one-year return of +10.2%.

With a market cap of $19.5 billion, ZBH is a large-cap stock. The company generates a free cash flow yield of 7.4%, which is healthy. Return on equity stands at 6.0%. The stock trades at 1.5x book value.

The company has been aggressively buying back shares, reducing its share count by 6.5% over the past three years.

Over the past 24.4 years, a hypothetical investment of $100 in ZBH would have grown to $330, compared to $1285 for the S&P 500. ZBH has returned 5.0% annualized vs 11.0% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 10% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: ZBH vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After ZBH Crosses Below the Line?

Across 18 historical episodes, buying ZBH when it crossed below its 200-week moving average produced an average return of +8.0% after 12 months (median +13.0%), compared to +8.9% for the S&P 500 over the same periods. 72% of those episodes were profitable after one year. After 24 months, the average return was +9.8% vs +20.7% for the index.

Each line shows $100 invested at the moment ZBH crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ZBH would reach each dislocation threshold.

Current Bean Score -1.52σ
Current FCF Yield 7.72%
Baseline Yield 9.02%
Historical σ 0.39pp

Dislocation Price Levels

Prices where ZBH's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-09-30).

LevelσPriceSignal
Deep Value+2σ$87.56Unusually cheap — analysis point
Value+1σ$91.50Cheap vs. own history
Fair Value+0σ$95.81Historical mean behavior
Expensive-1σ$100.55Expensive vs. own history
Deep Expensive-2σ$105.77Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-11-04$1.88$1.90+1.0%
2026-08-05$2.01$2.07+3.0%
2026-04-28$1.86$2.09+12.2%
2026-02-10$2.40$2.42+0.9%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from ZBH's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation +0.65σ Dividend yield vs own 10-yr norm
Drawdown Score +0.54σ Distance from line vs own history
Sector-Relative -0.02σ Vs sector median this week
Buyback Acceleration +0.4pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History +1.2pp Vs own recent annual mean
Earnings Quality Improving Accrual gap trend (-6.0pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

ZBH has crossed below its 200-week MA 18 times with an average 1-year return of +10.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jul 2002Jul 200223.5%+47.6%+296.2%
Apr 2006Aug 20061517.3%+44.7%+91.9%
Oct 2007Jan 20081415.0%-37.0%+76.8%
Feb 2008Mar 200820.3%-53.5%+60.3%
Apr 2008Jan 201114553.3%-40.2%+61.8%
Aug 2011Jan 20122215.2%+16.0%+126.8%
Nov 2016Nov 201611.8%+13.9%+17.8%
Nov 2016Dec 201610.1%+15.3%+15.3%
Mar 2018Apr 201855.2%+18.9%+6.4%
May 2018May 201810.2%+4.0%+2.7%
Jun 2018Jul 201810.1%+6.5%+2.1%
Jul 2018Jul 201810.1%+11.5%+1.9%
Nov 2018Jan 20191012.0%+28.7%+0.8%
Mar 2020May 20201028.7%+68.2%+15.1%
Jun 2020Jul 202033.6%+44.6%-3.0%
Nov 2021Apr 20237320.6%-8.0%-13.7%
May 2023Jun 202321.7%-8.1%-16.5%
Jul 2023Ongoing172+24.5%Ongoing-15.8%
Average27—+10.2%—

Frequently Asked Questions

Is ZBH below its 200-week moving average?

Yes. As of 2026-11-13, Zimmer Biomet Holdings, Inc. (ZBH) is trading 2.7% below its 200-week moving average of $106.09. The current price is $103.21.

What is ZBH's 200-week moving average price?

Zimmer Biomet Holdings, Inc.'s 200-week moving average is $106.09 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when ZBH drops below its 200-week moving average?

ZBH has crossed below its 200-week moving average 18 times in our data. On average, buying at that moment produced a one-year return of +10.2%. These dips have historically been decent entry points. These episodes lasted 27 weeks on average.

Is ZBH a good value right now?

Here's what our data says about ZBH as of 2026-11-13: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 57. Free cash flow yield is 7.4%. Return on equity is 6.0%. Price-to-book is 1.5x. This is not a buy or sell recommendation — always do your own research.

How does ZBH compare to the S&P 500?

Over the past 24.4 years, $100 invested in ZBH would have grown to $330, compared to $1285 for the S&P 500. That's 5.0% annualized vs 11.0% for the index. ZBH has underperformed the broader market over this period.

Does ZBH pay a dividend?

Yes. Zimmer Biomet Holdings, Inc. currently pays a dividend yield of 93.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13